Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation.

Last updated: August 27, 2024
Sponsor: Istituti Clinici Scientifici Maugeri SpA
Overall Status: Active - Recruiting

Phase

N/A

Condition

Respiratory Failure

Lung Injury

Treatment

placebo

effect of L-arginine and liposomial vitamin C on pulmonary rehabilitation

Clinical Study ID

NCT06439875
CTSM109-23
  • Ages 40-90
  • All Genders

Study Summary

The hypothesis that is being tested is that the supplementation of L-arginine plus Vitamin C to multidisciplinary pulmonary rehabilitation (PR) in patients with a previous diagnosis of chronic obstructive pulmonary disease (COPD) and chronic respiratory failure can have a favorable influence on fatigue and on clinical indicators related to endothelial function, potentially mitigating the cardiovascular (CV) disease burden in this clinical context.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • COPD patients of both sexes complicated by respiratory failure (PaO2 inferior to 60mmHg while breathing room air)

  • aged between 40 and 90 years selected from the inpatient/outpatient populationadmitted to perform a PR program in 12 Italian rehabilitation hospitals.

Exclusion

Exclusion criteria:

  • consuming any ergogenic supplement in the last 2 months;

  • severe acute exacerbations in the 3 months before enrolment;

  • clinical instability (pH inferior to 7.35, hemodynamic instability, tachypnea atrest);

  • lung restrictive diseases;

  • primitive pulmonary hypertension;

  • recent lung thromboembolic events;

  • orthopaedic clinical conditions interfering with exercise;

  • coronary heart disease;

  • cardiac failure with reduced ejection fraction;

  • major cardiac arrhythmias;

  • neuromuscular diseases;

  • mini mental state examination (MMSE) <24;

  • any prior or current medical problem that would limit the subject participation

Study Design

Total Participants: 102
Treatment Group(s): 2
Primary Treatment: placebo
Phase:
Study Start date:
July 16, 2024
Estimated Completion Date:
July 01, 2025

Study Description

The primary objective of this project is to assess the effects of L-arginine plus Vitamin C supplementation on the physical outcomes in a group of COPD patients with chronic respiratory failure who underwent a 28-day PR program.

Eligible participants will be randomized using a random number generator in a 1:1 ratio to receive a twice-daily oral supplementation with either a combination of 1.66 g l-arginine plus 500 mg liposomal vitamin C (Bioarginina® C, Farmaceutici Damor, Naples, Italy) or a placebo for 28 days. Vials containing the active supplement or the placebo will be supplied by Farmaceutici Damor and will be made indistinguishable in appearance. All patients will undergo an intensive multidisciplinary PR program based on endurance and strength training. The main outcome of the study is the fatigue severity scale (FSS) total score after rehabilitation. Secondary outcomes include: 6-minute walking distance, forced expiratory volume in the first second (FEV1), COPD assessment test (CAT) score, endothelial function assessed through flow-mediated dilation (FMD), and muscular strength assessed through handgrip measurement.

Anthropometric, clinical, and functional characteristics of the study participants will be reported as mean ± standard deviation (SD) or median (interquartile range, IQR) for continuous variables and as absolute values (percentages) for categorical variables. Changes from baseline for continuous variables will be expressed as deltas (values at 28 days minus the values at baseline), and differences between the interventional groups will be evaluated using the Student's t-test for normally distributed variables or the Mann-Whitney U test for skewed variables.

Connect with a study center

  • Istituti Clinici Scientifici Maugeri

    Telese Terme, Benevento 82037
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.